Citadel Advisors
RYTM icon

Citadel Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Citadel Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$339K Buy
+3,900
New +$379K ﹤0.01% 10188
2025
Q4 		– Sell
-3,000
Closed -$303K – 13880
2025
Q3 		$303K Sell
3,000
-25,300
-89% -$2.35M ﹤0.01% 10352
2025
Q2 		$1.79M Buy
28,300
+25,800
+1,032% +$1.58M ﹤0.01% 5916
2025
Q1 		$132K Sell
2,500
-8,100
-76% -$449K ﹤0.01% 11055
2024
Q4 		$593K Sell
10,600
-1,900
-15% -$105K ﹤0.01% 8183
2024
Q3 		$655K Sell
12,500
-5,600
-31% -$268K ﹤0.01% 7692
2024
Q2 		$743K Sell
18,100
-3,500
-16% -$140K ﹤0.01% 7230
2024
Q1 		$936K Buy
21,600
+8,200
+61% +$359K ﹤0.01% 7059
2023
Q4 		$616K Buy
13,400
+7,300
+120% +$230K ﹤0.01% 7646
2023
Q3 		$140K Sell
6,100
-3,000
-33% -$67.2K ﹤0.01% 10464
2023
Q2 		$150K Sell
9,100
-11,700
-56% -$211K ﹤0.01% 10338
2023
Q1 		$371K Buy
20,800
+16,900
+433% +$424K ﹤0.01% 8937
2022
Q4 		$114K Buy
+3,900
New +$100K ﹤0.01% 11047
2021
Q3 		– Sell
-12,100
Closed -$237K – 14534
2021
Q2 		$237K Sell
12,100
-2,900
-19% -$60.2K ﹤0.01% 11804
2021
Q1 		$319K Sell
15,000
-1,800
-11% -$52.2K ﹤0.01% 10713
2020
Q4 		$499K Sell
16,800
-8,500
-34% -$216K ﹤0.01% 8148
2020
Q3 		$548K Buy
+25,300
New +$580K ﹤0.01% 7128

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Citadel Advisors's RYTM Position: Q1 2026 in Review

Citadel Advisors increased its Rhythm Pharmaceuticals (RYTM) stake by 825% in Q1 2026, buying an estimated $123M and bringing the position to 1,418,619 shares worth $123M. The position accounts for 0.02% of the portfolio, ranked #685.

Citadel Advisors first reported a position in RYTM in Q4 2017 and has held it in 25 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Citadel Advisors held 1,418,619 shares of Rhythm Pharmaceuticals worth $123M as of Q1 2026.
  • Citadel Advisors bought 1,265,297 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $123M.
  • Rhythm Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #685 holding.
  • Citadel Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 25 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.